ERBB2 and breast cancer: Using the National Cancer Database (NCDB), we evaluated national trends in axillary surgery management in patients with pathologic T0–T2 estrogen receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2−) breast cancer with 3–5 positive lymph nodes who underwent surgery followed by adjuvant systemic and radiation treatments, and the impact of SLNB versus ALND on OS in this patient population.